Risk factors

Hycroft faces severe execution risks centered on restarting the non-producing Hycroft Mine without current mineral reserves or a definitive restart plan. The company is completely dependent on this single Nevada property, leaving its financials vulnerable to volatile gold and silver prices, complex permitting, and the need for significant future capital.

Immunome faces heavy risks around financing, clinical trial execution, regulatory approval, and building commercial capabilities for products like varegacestat and IM-1021.

Ingram Micro highlights new risks from HPE's acquisition of Juniper, broader global tariffs, and executive change-of-control incentives. Macroeconomic uncertainty, vendor consolidation, and strict regulatory and ESG compliance continue to drive core operational risks.

James River Group Holdings expanded risks around its U.S. corporate domestication, tax structures, and new artificial intelligence vulnerabilities. The company updated reinsurance exposures, showing $936.9 million recoverable from its top three reinsurers in 2025.

Mining revenue exposure decreased to 4 percent of consolidated revenue in 2025.

Integration and operational risks related to the Provident Acquisition dominate the newly added risk factors.

NeuroPace faces supply chain and single-source component risks for its RNS System.

OFS Capital Corp added specific macro threats like trade policy tariffs, public health crises, and ESG public scrutiny risks.

Passage Bio added risks regarding accelerated FDA approvals, healthcare fraud laws, and privacy regulations. Budget Control Act Medicare cuts were extended through 2032.

Prime Medicine added 11 new risk disclosures covering financial instability, regulatory complexities for gene editing, data privacy, ESG, and social media. The company updated risks on collaboration dependencies, macroeconomic factors, and patent protection standards.

Quantum-Si highlights transition risks as customers delay purchases ahead of the planned 2026 Proteus platform launch. The company reports escalating net losses, an accumulated deficit reaching $698.0 million, and ongoing Nasdaq compliance risks.

Rigel expanded commercial operations with REZLIDHIA for R/R AML and settled Annora generic litigation for TAVALISSE. The company faced increased scrutiny on pricing methodologies and drug rebate reporting compliance. Regulatory hurdles grew with new EU health technology assessment regulations and UK orphan drug rules.